| |
No adjuvant therapy
|
Tamoxifen monotherapy
|
|---|
|
Factors
|
Bcl-2
| |
P-value
|
Bcl-2
| |
P-value
|
|---|
| |
+ (%)
|
-
| |
+ (%)
|
-
| |
|---|
|
Menopause
| | |
0.0049*
| | |
0.1249
|
|
Post
|
156 (58)
|
112
| |
191 (64)
|
108
| |
|
Pre
|
210 (70)
|
92
| |
117 (71)
|
48
| |
|
Tumor size
| |
0.0023*
| |
0.0051*
|
|
>20 mm
|
199 (58)
|
143
| |
178 (61)
|
112
| |
|
≤20 mm
|
204 (70)
|
88
| |
138 (74)
|
49
| |
|
Node
| |
0.9049
| |
0.2938
|
|
+
|
96 (63)
|
56
| |
141 (64)
|
80
| |
|
-
|
307 (64)
|
175
| |
175 (68)
|
81
| |
|
Grade
| |
<0.0001*
| |
0.0040*
|
|
II + III
|
244 (54)
|
205
| |
170 (61)
|
109
| |
|
I
|
157 (86)
|
26
| |
145 (74)
|
52
| |
|
ER
| |
<0.0001*
| |
<0.0001*
|
|
+
|
330 (88)
|
45
| |
290 (74)
|
100
| |
|
-
|
71 (28)
|
186
| |
26 (30)
|
61
| |
|
PR
| |
<0.0001*
| |
<0.0001*
|
|
+
|
242 (89)
|
30
| |
189 (76)
|
59
| |
|
-
|
159 (44)
|
200
| |
127 (55)
|
102
| |
|
HER2
| |
<0.0001*
| |
0.0005*
|
|
+
|
19 (21)
|
70
| |
8 (33)
|
16
| |
|
-
|
381 (70)
|
160
| |
308 (68)
|
145
| |
|
Total
|
634
| |
477
| |
- *Significant, P < 0.05/7 = 0.0071 (Bonferroni adjustment)
- Post and Pre postmenopause and premenopause at the time of diagnosis, + positive, − negative, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2
